RegeneRx (RGN) Receives Patent Approval for Tβ4 Use in Australia
RegeneRx Biopharmaceuticals, Inc. (NYSE: RGN) announced Wednesday that it has received patent approval in Australia for the use of thymosin beta 4 for the treatment of a broad array of gastrointestinal infections and disorders.
The company said that the patent expires in 2023.
RegeneRx has patents pending for the treatment's use in several countries including the U.S.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The company said that the patent expires in 2023.
RegeneRx has patents pending for the treatment's use in several countries including the U.S.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- BlackRock (BLK) Substantially Boosts Stake in Chesapeake (CHK) -CNBC's Kelly
- IntercontinentalExchange (ICE) says daily crude volume hits record in May
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
